26 related articles for article (PubMed ID: 1808112)
1. Contrast-enhanced magnetic resonance imaging of the liver.
Van Beers B
J Belge Radiol; 1997 Dec; 80(6):322. PubMed ID: 9479919
[No Abstract] [Full Text] [Related]
2. Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice.
Pedchenko TV; LeVine SM
J Neuroimmunol; 1998 Apr; 84(2):188-97. PubMed ID: 9628462
[TBL] [Abstract][Full Text] [Related]
3. Ferrioxamine B analogues: targeting the FoxA uptake system in the pathogenic Yersinia enterocolitica.
Kornreich-Leshem H; Ziv C; Gumienna-Kontecka E; Arad-Yellin R; Chen Y; Elhabiri M; Albrecht-Gary AM; Hadar Y; Shanzer A
J Am Chem Soc; 2005 Feb; 127(4):1137-45. PubMed ID: 15669853
[TBL] [Abstract][Full Text] [Related]
4. High-performance liquid chromatography of deferoxamine and ferrioxamine: interference by iron present in the chromatographic system.
Cramer SM; Nathanael B; Horváth C
J Chromatogr; 1984 Jul; 295(2):405-11. PubMed ID: 6432830
[TBL] [Abstract][Full Text] [Related]
5. An ovine model of maternal iron poisoning in pregnancy.
Curry SC; Bond GR; Raschke R; Tellez D; Wiggins D
Ann Emerg Med; 1990 Jun; 19(6):632-8. PubMed ID: 2344079
[TBL] [Abstract][Full Text] [Related]
6. Hepatic transport of magnetic resonance imaging contrast agents. Ferrioxamine B derivatives.
White DL; Eason RG; Alkire AL; Price DC; Hoener BA; Milco LA; Keen RE; Barnhart JL
Invest Radiol; 1991 Nov; 26 Suppl 1():S146-7; discussion S150-5. PubMed ID: 1808112
[No Abstract] [Full Text] [Related]
7. Imaging circulating cells and lymphoid tissues with iron oxide nanoparticles.
Elias A; Tsourkas A
Hematology Am Soc Hematol Educ Program; 2009; ():720-6. PubMed ID: 20008258
[TBL] [Abstract][Full Text] [Related]
8. Paramagnetic iron (III) MRI contrast agents.
White DL
Magn Reson Med; 1991 Dec; 22(2):309-12. PubMed ID: 1812362
[No Abstract] [Full Text] [Related]
9. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
Porter JB; Rafique R; Srichairatanakool S; Davis BA; Shah FT; Hair T; Evans P
Ann N Y Acad Sci; 2005; 1054():155-68. PubMed ID: 16339661
[TBL] [Abstract][Full Text] [Related]
10. [Liver-specific MR contrast agents: current status and prospects].
Tanimoto A
Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Sep; 61(10):525-33. PubMed ID: 11676169
[TBL] [Abstract][Full Text] [Related]
11. Imaging of inflammation in the peripheral and central nervous system by magnetic resonance imaging.
Stoll G; Bendszus M
Neuroscience; 2009 Feb; 158(3):1151-60. PubMed ID: 18651996
[TBL] [Abstract][Full Text] [Related]
12. Using radiotracers to characterize magnetic resonance imaging contrast agents.
Tweedle MF
Invest Radiol; 2002 Mar; 37(3):107-13. PubMed ID: 11882789
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
